265137-38-0

Upstream product

• 265137-37-9 4,4-dimethyl-2-(1-oxo-1,3-dihydroisobenzofuran-5-yl)oxazoline 
• 19070-16-7 3-(N,N-dimethylamino)propylmagnesium chloride 
• 352-13-6 4-flourophenylmagnesium bromide 

Downstream Products

• 265137-39-1 4,4-dimethyl-2-[1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl]oxazoline 
• 59729-33-8 1-(3-dimethylamino-propyl)-1-(4-fluoro-phenyl)-1,3-dihydro-isobenzofuran-5-carbonitrile 

Relevant academic research and scientific papers

Process for the preparation of citalopram

Preparation of citalopram comprises the steps of: (a) converting the compound of Formula (I) to a compound of Formula (II), wherein R in Formula (I) represents a C2 to C5 alkylene group which may be substituted or unsubstituted, and R1 in the compounds of Formula (II) represents a carboxylic acid group or a salt or an ester thereof; and (b) converting the compound of Formula (II) to form citalopram or a pharmaceutically acceptable salt thereof, or a direct conversion of the compound of Formula (I) to citalopram

Method for the preparation of citalopram

The present invention relates to a method for the preparation of citalopram or any of its enantiomers and acid addition salts thereof comprising treatment of a compound of formula (IV), wherein X is O or S; R1-R2are each independently selected from hydrogen and C1-6alkyl, or R1and R2together form a C2-5alkylene chain thereby forming a spiro-ring; R3is selected from hydrogen and C1-6alkyl, R4is selected from hydrogen, C1-6alkyl, a carboxy group or a precursor group therefore, or R3and R4together form a C2-5alkylene chain thereby forming a spiro-ring, with a dehydration agent or alternatively where X is S, thermally cleavage of the thiazoline ring, or treatment in presence of a radical initiator, to form citalopram. The invention also relates to intermediates used in the new process for the preparation of citalopram, as well as citalopram prepared according to the new process.